Neuronetics price target raised to $7 from $3 at Citizens JMP

Citizens JMP raised the firm’s price target on Neuronetics (STIM) to $7 from $3 and keeps an Outperform rating on the shares. Neuronetics’ Top-line quarterly results came in moderately ahead of the company’s mid-January preliminary announcement, and full-year 2025 guidance was maintained, the analyst tells investors in a research note. The stock’s nearly 20% increase on Tuesday was most likely from additional commentary on what has been driving the stock higher year to date — the potential growth, scale, and patient reach that the combined entity could achieve as a vertically integrated mental healthcare provider following the merger with Greenbrook TMS, the firm says.